Recurrent inflammatory pseudotumor of the jaw with perineural intracranial invasion demonstrating sustained response to Rituximab.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Garcia BA;Garcia BA; Tinsley S; Schellenberger T; Bobustuc GC
  • Source:
    Medical oncology (Northwood, London, England) [Med Oncol] 2012 Dec; Vol. 29 (4), pp. 2452-5. Date of Electronic Publication: 2011 Dec 08.
  • Publication Type:
    Case Reports; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE
    • Publication Information:
      Publication: 2011- : New York : Springer
      Original Publication: Northwood, Middlesex, England : Science and Technology Letters, c1994-
    • Subject Terms:
      Antibodies, Monoclonal, Murine-Derived/*therapeutic use ; Antineoplastic Agents/*therapeutic use ; Granuloma, Plasma Cell/*drug therapy ; Mandibular Diseases/*drug therapy ; Meninges/*pathology; Adult ; Granuloma, Plasma Cell/pathology ; Humans ; Male ; Mandibular Diseases/pathology ; Neoplasm Invasiveness ; Recurrence ; Rituximab
    • Abstract:
      Corticosteroids are the mainstay of treatment of inflammatory pseudotumor (IPT) of the head and neck; however, involvement of the skull base and mandible can be unresponsive to steroids and require surgical resection. IPT is known to usually contain a CD20+ lymphocyte subgroup. Rituximab, a chimeric anti-CD20 antibody, has been successfully utilized in the treatment of other CD20+ diseases, including the similar idiopathic orbital inflammatory disease. This is the first report to describe successful treatment with Rituximab of a recurrent IPT of the mandible with trigeminal spread and leptomeningeal involvement with clinical and radiologic evidence demonstrating a sustained response to therapy.
    • References:
      Otolaryngol Head Neck Surg. 2006 Jul;135(1):144-8. (PMID: 16815200)
      AJNR Am J Neuroradiol. 2009 Nov;30(10):1941-3. (PMID: 19749214)
      Clin Rheumatol. 2009 Feb;28(2):225-6. (PMID: 19015801)
      Clin Exp Med. 2011 Mar;11(1):61-3. (PMID: 20844916)
      Tissue Antigens. 2007 Aug;70(2):105-9. (PMID: 17610415)
      AJNR Am J Neuroradiol. 2011 Sep;32(8):E150-2. (PMID: 20864523)
      Radiographics. 2003 May-Jun;23(3):719-29. (PMID: 12740472)
      Am J Surg Pathol. 2001 May;25(5):624-9. (PMID: 11342774)
      AJR Am J Roentgenol. 2009 Oct;193(4):1180-6. (PMID: 19770345)
      Head Neck Pathol. 2010 Mar;4(1):44-8. (PMID: 20237988)
      Hum Pathol. 1995 Oct;26(10):1093-8. (PMID: 7557942)
      Curr Oncol Rep. 2011 Oct;13(5):386-97. (PMID: 21845421)
      Ear Nose Throat J. 2010 Jul;89(7):E1-13. (PMID: 20628971)
      Case Rep Oncol. 2011 May;4(2):304-10. (PMID: 21734886)
    • Accession Number:
      0 (Antibodies, Monoclonal, Murine-Derived)
      0 (Antineoplastic Agents)
      4F4X42SYQ6 (Rituximab)
    • Publication Date:
      Date Created: 20111214 Date Completed: 20130726 Latest Revision: 20211021
    • Publication Date:
      20240829
    • Accession Number:
      10.1007/s12032-011-0128-1
    • Accession Number:
      22161155